[1]Department of Pathology and Laboratory Medicine;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[2]Center for Cellular Immunotherapies;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[1]Department of Pathology and Laboratory Medicine;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[2]Center for Cellular Immunotherapies;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[3]Parker Institute for Cancer Immunotherapy;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[1]Department of Pathology and Laboratory Medicine;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[2]Center for Cellular Immunotherapies;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[3]Parker Institute for Cancer Immunotherapy;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[4]Abramson Cancer Center;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[5]Department of Immunology;
Peking University;
Beijing 100871;
China;
[1]Department of Pathology and Laboratory Medicine;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[2]Center for Cellular Immunotherapies;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[3]Parker Institute for Cancer Immunotherapy;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[1]Department of Pathology and Laboratory Medicine;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[2]Center for Cellular Immunotherapies;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
[3]Parker Institute for Cancer Immunotherapy;
University of Pennsylvania;
Philadelphia;
PA 19104;
USA;
Engineered T cell therapies; Chimeric antigen receptor; Drug development process; Biomarkers; CD19-specific chimeric antigen receptor; Anti-CD19 chimeric antigen receptor T cells;